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BACKGROUND: There are few population-based childhood cancer registries in the world containing stage and treatment data.
METHODS: Data from the population-based Australian Paediatric Cancer Registry were used to calculate incidence rates during the
most recent 10-year period (1997–2006) and trends in incidence between 1983 and 2006 for the 12 major diagnostic groups of the
International Classification of Childhood Cancer.
RESULTS: In the period 1997–2006, there were 6184 childhood cancer (at 0–14 years) cases in Australia (157 cases per million
children). The commonest cancers were leukaemia (34%), that of the central nervous system (23%) and lymphomas (10%), with
incidence the highest at 0–4 years (223 cases per million). Trend analyses showed that incidence among boys for all cancers
combined increased by 1.6% per year from 1983 to 1994 but have remained stable since. Incidence rates for girls consistently
increased by 0.9% per year. Since 1983, there have been significant increases among boys and girls for leukaemia, and hepatic and
germ-cell tumours, whereas for boys, incidence of neuroblastomas and malignant epithelial tumours has recently decreased. For all
cancers and for both sexes combined, there was a consistent increase (þ0.7% per year, 1983–2006) at age 0–4 years, a slight non-
significant increase at 5–9 years, and at 10–14 years, an initial increase (2.7% per year, 1983–1996) followed by a slight non-
significant decrease.
CONCLUSION: Although there is some evidence of a recent plateau in cancer incidence rates in Australia for boys and older children,
interpretation is difficult without a better understanding of what underlies the changes reported.
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Although childhood cancers (0–14 years) are rare, they were the
second commonest cause of death (17% of deaths) among
Australian children aged 1–14 years in 2004–2006, after injuries
(Australian Institute of Health and Welfare, 2009).
In addition to the loss of life, the burden of childhood cancer
extends to the long-term adverse health effects experienced by a
large proportion of childhood cancer survivors, either because of
the cancer itself or its treatment. (Hudson et al, 2003; Aziz et al,
2006; Goldsby et al, 2006; Maule et al, 2007; Kurt et al, 2008;
Mertens et al, 2008; Oeffinger et al, 2008) There is also some
evidence that childhood cancer and its treatment can have
persisting negative effects on parents (Hardy et al, 2008) in
relation to both finance and lifestyle(Cohn et al, 2003).
Children’s cancer registries need to be specially designed (Cole,
2004). The Australian Paediatric Cancer Registry (APCR), one of
the few population-based childhood cancer registries in the world,
was first established in 1977, with full population-based coverage
from 1983. Although information on cancer for all ages is available
through State and Territory Cancer Registries within Australia, no
other Australian registry collects detailed information on the stage
of disease and treatment of childhood cancer. Such information is
required for setting and measuring standards of care for children
with cancer and to track changes in outcome over time.
Following a report on rising incidence rates for childhood
cancer in Australia between 1982 and 1991 (McWhirter et al, 1996),
this paper reports the latest Australian population-based incidence
rates and long-term trends up to 2006 using the current
International Classification of Childhood Cancers.
MATERIALS AND METHODS
Notification of invasive cancer is a statutory requirement for all
public and private hospitals and pathology services in Australia;
therefore, the incidence data reported here are considered to
represent the entire Australian population aged 0–14 years
(approximately 4 million children in 2006). Cancer notifications
are sent initially to state- and territory-based cancer registries, and
then, for most states and territories, these notifications are
transferred directly to the APCR. In those states in which
legislation precludes this direct transfer, diagnostic information
is accessed by the treating hospital in consultation with the state
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validation of cancer records is achieved through site visits by the
APCR Data Manager to major children’s hospitals throughout
Australia, when information on clinical characteristics and
treatment is extracted from patients’ charts.
In contrast to the coding system for adult cancers that is based
on site, the internationally recognised childhood cancer classifica-
tion is based on morphology (Steliarova-Foucher et al, 2005b). The
current standard for childhood cancer is the International
Classification of Childhood Cancers (ICCC-3) (Steliarova-Foucher
et al, 2005b), which classifies tumours coded according to the ICD-
O-3 nomenclature into the 12 major diagnostic groups shown in
Table 1 (Steliarova-Foucher et al, 2005b).
Although tumours of benign or uncertain behaviour are
generally not reported for adults, the ICCC-3 includes non-
malignant intracranial and intraspinal tumours in categories III
and X (see Tables 1 and 2) (Steliarova-Foucher et al, 2005b). In
accordance with this accepted classification throughout this paper,
childhood cancer refers to all malignant tumours, as well as to
intracranial and intraspinal tumours of benign or uncertain
behaviour. In those Australian states that do not collect informa-
tion on tumours of benign or uncertain behaviour, such cases
were captured through the major paediatric treating hospitals in
that state.
Numerical indices of data quality were calculated for the
diagnostic criteria of histological verification (HV) and death
certificate only (DCO) (Bray and Parkin, 2009). Histological
verification includes diagnoses based on histology of primary,
exfoliative cytology and haematological examination of peripheral
blood, histology of metastasis and autopsy with histology.
These indices were calculated separately for two 10-year periods
(1987–96 and 1997–2006).
Incidence rates were calculated for each cancer category,
separately for each sex and age group (0–4 years, 5–9 years and
10–14 years) over the most recent 10-year period (1997–2006).
Rates were age standardised to the WHO World Standard
Population (Ahmad et al, 2001) and expressed per million
population.
We used JoinPoint (National Cancer Institute, 2008) software to
examine trends in incidence rates from 1983 to 2006, specifically to
assess whether the magnitude or direction of trend changed during
this period, and to quantify the annual percentage change (APC).
To reduce the likelihood of reporting spurious changes in trends,
we used a maximum of two joinpoints (i.e., up to three different
trends), with a minimum of 8 years between joinpoints. The trend
lines that provided the best fit to observed data, based on Monte
Carlo permutation tests, were selected.
RESULTS
During the period 1983–2006, 13925 childhood cancers were
diagnosed in Australia; 95.4% of records were based on
histological verification (HV), including 74.0% based on histology
of primary, 20.7% on cytology or haematology, 0.3% on histology
of metastasis and 0.4% on autopsy with histology. Of the
remainder, most were clinical investigations (3.9% of total) or
clinical only (0.2%). Less than 0.2% of diagnoses were based on
death certificate only, with 0.3% having unknown histology.
Between 1987 and 1996 and 1997 and 2006, there was a reduction
in the percentage of records based on HV, from 96.8 to 93.9%
(Table 1). This was mainly because of an increase in the proportion
of records based on clinical investigations, from 2.9 to 5.1% for all
childhood cancers, from 10.0 to 17.2% for central nervous system
(CNS) and from 7.7 to 12.2% for retinoblastoma; the reasons
are unclear.
In the most recent 10-year period, 1997–2006, a total of 6184
children under the age of 15 years were diagnosed with cancer in
Australia (Table 2), equivalent to an annual age-standardised rate
of 157 cases per million. Nine in 10 (91%) of these cancers were
malignant. The remainder, 568 tumours, or 14 cases per million
population were of benign or uncertain behaviour in the brain or
central nervous system; the commonest types were leukaemia
(34%), CNS (23%) and lymphomas (10%).
There was a 1.14:1 male/female ratio for overall childhood
cancer incidence (Table 3), with a marked difference between age
groups. The incidence rate of childhood cancer was higher
among children aged 0–4 years (223 cases per million population)
than at ages 5–9 (117 per million) or 10–14 years (131 per
million). Some exceptions to this age-specific pattern were
shown by lymphomas, malignant bone tumours and malignant
epithelial tumours and melanomas in which incidence was highest
at 10–14 years.
Childhood cancer incidence increased between 1983 and 1994
for boys (þ1.6% per year), but has remained stable since then
(Figure 1; Table 4). The overall trend among girls increased by an
average of 0.9% per year over the entire period, 1983–2006
(Table 4).
Trends varied substantially by cancer type, although the small
number of specific cancers often resulted in substantial year-to-
year random fluctuations in rates even when the underlying trend
was statistically significant. Notably, incidence trends among both
boys and girls for leukaemia, hepatic tumours and germ cell
tumours showed significant increases, whereas there have been
recent, significant decreases among boys in the incidence of
neuroblastomas and malignant epithelial tumours and melanomas
Table 1 Indices of data quality by diagnostic group
1987–1996 1997–2006
Diagnostic group
Cases
1983–2006 %DCO
a %HV
b %DCO
a %HV
b
All cancers 13925 0.1 96.8 0.1 93.9
I. Leukaemias, myeloproliferative diseases, and myelodysplastic diseases (‘Leukaemias’) 4591 0.1 99.7 0.1 98.7
II. Lymphomas and reticuloendothelial neoplasms (‘Lymphomas’) 1374 0.2 99.3 0.0 99.4
III. CNS and miscellaneous intracranial and intraspinal neoplasms (‘CNS’)
c 3158 0.3 89.5 0.0 81.4
IV. Neuroblastoma and other peripheral nervous cell tumours (‘Neuroblastoma’) 869 0.0 96.1 0.0 97.0
V. Retinoblastomas 357 0.0 91.5 0.0 82.4
VI. Renal tumours 735 0.0 100.0 0.0 97.9
VII. Hepatic tumours 174 1.6 98.4 1.0 94.9
VIII. Malignant bone tumours 602 0.0 99.6 0.0 97.3
IX. Soft tissue and other extraosseous sarcomas (‘Soft tissue’) 820 0.0 98.9 0.0 97.6
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads (‘Germ cell’)
c 511 0.0 97.0 0.8 93.6
XI. Other malignant epithelial neoplasms and malignant melanomas 705 0.0 99.7 0.3 98.8
XII. Other and unspecified malignant neoplasms 29 0.0 100.0 0.0 85.7
aHV ¼ Histological vertification.
bDCO ¼ Death certificate only.
cCategory includes tumours of benign or uncertain behaviour.
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a,b
Diagnostic group/subgroup
Average number
of cases per year (%)
Rate per million
population per year (95% CI)
All cancers 618.4 100.0 157.5 (153.6–161.5)
I. Leukaemias, myeloproliferative diseases, and myelodysplastic diseases (‘Leukaemias’) 207.2 33.5 53.1 (50.8–55.4)
a. Lymphoid leukaemias 159.0 25.7 40.8 (38.8–42.8)
b. Acute myeloid leukaemias 34.3 5.5 8.7 (7.8–9.7)
c. Chronic myeloproliferative diseases 6.9 1.1 1.7 (1.4–2.2)
d. Other myeloproliferative diseases 4.8 0.8 1.2 (0.9–1.6)
e. Other and unspecified leukaemias 2.2 0.4 0.6 (0.4–0.9)
II. Lymphomas and reticuloendothelial neoplasms (‘Lymphomas’) 62.0 10.0 15.4 (14.2–16.7)
a. Hodgkin’s lymphomas 26.0 4.2 6.4 (5.6–7.2)
b. Non-Hodgkin’s lymphomas (excl. Burkitt lymphomas) 21.8 3.5 5.4 (4.8–6.2)
c. Burkitt lymphomas 12.4 2.0 3.1 (2.6–3.7)
d. Miscellaneous lymphoreticular neoplasms 1.1 0.2 0.3 (0.1–0.5)
e. Unspecified lymphomas 0.7 0.1 0.2 (0.1–0.4)
III. CNS and miscellaneous intracranial and intraspinal neoplasms (‘CNS’)
c 140.5 22.7 35.7 (33.8–37.6)
a. Ependyomas and choroid plexus tumours
c 13.1 2.1 3.4 (2.8–4.0)
b. Astrocytomas
c 63.9 10.3 16.2 (15.0–17.5)
c. Intracranial and intraspinal embryonal tumours
c 28.0 4.5 7.2 (6.3–8.0)
d. Other gliomas
c 16.5 2.7 4.2 (3.5–4.8)
e. Other specified intracranial and intraspinal neoplasms
c 15.5 2.5 3.9 (3.3–4.6)
f. Unspecified intracranial and intraspinal neoplasms
c 3.5 0.6 0.9 (0.6–1.2)
IV. Neuroblastoma and other peripheral nervous cell tumours (‘Neuroblastomas’) 36.6 5.9 9.6 (8.7–10.7)
a. Neuroblastomas and ganglioneuroblastomas 36.0 5.8 9.5 (8.5–10.5)
b. Other peripheral nervous cell tumours 0.6 0.1 0.2 (0.1–0.3)
V. Retinoblastomas 14.8 2.4 3.9 (3.3–4.6)
VI. Renal tumours 32.5 5.3 8.5 (7.6–9.5)
a. Nephroblastomas and other nonepithelial renal tumours 31.2 5.0 8.2 (7.3–9.1)
b. Renal carcinomas 1.1 0.2 0.3 (0.1–0.5)
c. Unspecified renal tumours 0.2 0.0 0.1 (0.0–0.2)
VII. Hepatic tumours 9.8 1.6 2.6 (2.1–3.1)
a. Hepatoblastomas 8.0 1.3 2.1 (1.7–2.6)
b. Hepatic carcinomas 1.6 0.3 0.4 (0.2–0.6)
c. Unspecified hepatic tumours 0.2 0.0 0.1 (0.0–0.2)
VIII. Malignant bone tumours 26.3 4.3 6.5 (5.7–7.3)
a. Osteosarcomas 12.1 2.0 3.0 (2.5–3.5)
b. Chondrosarcomas 0.4 0.1 0.1 (0.0–0.2)
c. Ewing tumours and related bone sarcomas 12.5 2.0 3.1 (2.6–3.7)
d. Other specified bone tumours 0.7 0.1 0.2 (0.1–0.4)
e. Unspecified bone tumours 0.6 0.1 0.1 (0.1–0.3)
IX. Soft tissue and other extraosseous sarcomas (‘Soft tissue’) 33.2 5.4 8.4 (7.5–9.4)
a. Rhabdomyosarcomas 16.5 2.7 4.2 (3.6–4.9)
b. Fibrosarcomas and other fibrous neoplasms 3.1 0.5 0.8 (0.5–1.1)
c. Kaposi sarcomas 0.0 0.0 —
d. Other specified soft tissue sarcomas 11.8 1.9 2.9 (2.4–3.5)
e. Unspecified soft tissue sarcomas 1.8 0.3 0.5 (0.3–0.7)
X. Germ cell tumors, trophoblastic tumours, and neoplasms of gonads (‘Germ cell’)
c 25.1 4.1 6.4 (5.7–7.3)
a. Intracranial and intraspinal germ cell tumours
c 7.1 1.1 1.8 (1.4–2.3)
b. Extracranial and extragonodal germ cell tumours 7.7 1.2 2.0 (1.6–2.5)
c. Gonadal germ cell tumours 9.7 1.6 2.5 (2.0–3.0)
d. Gonadal carcinomas 0.5 0.1 0.1 (0.0–0.3)
e. Other and unspecified gonodal tumours 0.1 0.0 0.0 (0.0–0.1)
XI. Other malignant epithelial neoplasms and malignant melanomas 29.0 4.7 7.1 (6.3–8.0)
a. Adrenocortical carcinomas 1.3 0.2 0.3 (0.2–0.6)
b. Thyroid carcinomas 5.3 0.9 1.3 (1.0–1.7)
c. Nasopharyngeal carcinomas 1.0 0.2 0.2 (0.1–0.4)
d. Melanomas 14.3 2.3 3.5 (3.0–4.1)
e. Skin carcinomas 1.0 0.2 0.2 (0.1–0.5)
f. Other and unspecified carcinomas 6.1 1.0 1.5 (1.1–1.9)
XII. Other and unspecified malignant neoplasms 1.4 0.2 0.4 (0.2–0.6)
a. Other specified malignant tumours 1.0 0.2 0.3 (0.1–0.5)
b. Other unspecified malignant tumours 0.4 0.1 0.1 (0.0–0.3)
aDiagnostic groups defined using the International Classification of Childhood Cancers (ICCC-3) Goldsby et al, 2006.
bRates age-standardised to the WHO World Standard
Population Howard et al, 2008.
cCategory includes tumours of benign or uncertain behaviour.
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‘other and unspecified malignant neoplasms’, we did not assess
trends for this category.
There was also some variation in incidence rate trends by age
group (Table 4). At 0–4 years, the average increase (þ0.7% per
year) was consistent upto 2006, but at 5–9 years there was
Table 3 Average annual incidence by sex and 5-year age group, Australia, 1997–2006
a,b
Diagnostic group Males Females 0–4 years 5–9 years 10–14 years
All childhood cancers
Average cases per year 336.7 281.7 284.6 156.4 177.4
Rate per million 167.2 147.2 222.9 117.2 130.8
95% CI (161.6–173.0) (141.8–152.8) (214.8–231.2) (111.4–123.1) (124.8–137.0)
I. Leukaemias
Average cases per year 112.9 94.3 108.0 55.2 44.0
Rate per million 56.4 49.6 84.6 41.4 32.4
95% CI (53.1–59.8) (46.5–52.9) (79.6–89.8) (38.0–44.9) (29.5–35.6)
II. Lymphomas
Average cases per year 42.4 19.6 10.2 19.1 32.7
Rate per million 20.6 10.0 8.0 14.3 24.1
95% CI (18.7–22.6) (8.6–11.4) (6.5–9.7) (12.4–16.5) (21.6–26.9)
III. CNS
c
Average cases per year 75.4 65.1 55.8 47.6 37.1
Rate per million 37.3 33.9 43.7 35.7 27.4
95% CI (34.7–40.0) (31.4–36.6) (40.2–47.5) (32.5–39.0) (24.6–30.3)
IV. Neuroblastomas
Average cases per year 18.7 17.9 32.0 3.5 1.1
Rate per million 9.6 9.7 25.1 2.6 0.8
95% CI (8.3–11.1) (8.3–11.2) (22.4–28.0) (1.8–3.6) (0.4–1.5)
V. Retinoblastomas
Average cases per year 8.9 5.9 14.0 0.8 0.0
Rate per million 4.6 3.2 11.0 0.6 —
95% CI (3.7–5.6) (2.4–4.1) (9.2–12.9) (0.3–1.2) —
VI. Renal tumours
Average cases per year 14.4 18.1 24.8 5.9 1.8
Rate per million 7.3 9.7 19.4 4.4 1.3
95% CI (6.2–8.6) (8.3–11.2) (17.1–22.0) (3.4–5.7) (0.8–2.1)
VII. Hepatic tumours
Average cases per year 6.2 3.6 7.7 1.0 1.1
Rate per million 3.2 1.9 6.0 0.7 0.8
95% CI (2.4–4.0) (1.4–2.7) (4.8–7.5) (0.4–1.4) (0.4–1.5)
VIII. Malignant bone tumours
Average cases per year 13.1 13.2 2.5 6.6 17.2
Rate per million 6.3 6.7 2.0 4.9 12.7
95% CI (5.3–7.5) (5.6–7.9) (1.3–2.9) (3.8–6.3) (10.9–14.7)
IX. Soft tissue sarcomas
Average cases per year 18.7 14.5 12.8 8.7 11.7
Rate per million 9.3 7.5 10.0 6.5 8.6
95% CI (8.0–10.7) (6.3–8.8) (8.4–11.9) (5.2–8.0) (7.1–10.3)
X. Germ cell tumours
c
Average cases per year 12.4 12.7 13.8 3.2 8.1
Rate per million 6.3 6.6 10.8 2.4 6.0
95% CI (5.2–7.5) (5.5–7.9) (9.1–12.8) (1.6–3.4) 6.0 (4.7–7.4)
XI. Malignant epithelial tumours and melanomas
Average cases per year 12.6 16.4 2.3 4.8 21.9
Rate per million 6.0 8.3 1.8 3.6 16.1
95% CI (5.0–7.2) (7.0–9.6) (1.1–2.7) (2.7–4.8) (14.1–18.4)
XII. Other and unspecified malignant neoplasms
Average cases per year 1.0 0.4 0.7 0.0 0.7
Rate per million 0.5 0.2 0.5 — 0.5
95% CI (0.2–0.9) (0.1–0.5) (0.2–1.1) — (0.2–1.1)
aDiagnostic groups defined using the International Classification of Childhood Cancers (ICCC-3) Goldsby et al, 2006.
bRates age-standardised to the WHO World Standard
Population Howard et al, 2008.
cCategory includes tumours of benign or uncertain behaviour.
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time; at 10–14 years, the initial significant increase of 2.7% per
year peaked in 1996, followed by a small, but not significant
decrease in incidence.
DISCUSSION
Whereas direct comparisons with international incidence rates can
be problematic because of different population standards and
disease classifications, the world age-standardised incidence rates
we report here (158 per million) are among the highest reported
internationally (Desandes et al, 2004; Steliarova-Foucher et al,
2005a; Stack et al, 2007; Li et al, 2008; Linabery and Ross, 2008;
Ocheni et al, 2008; Spix et al, 2008; Swaminathan et al, 2008). This
is consistent with the finding that incidence shows a strong
positive association with the national per capita gross income
levels (Howard et al, 2008).
The distribution of paediatric cancer was similar to that
reported in other countries, particularly in more developed
countries. Leukaemia made up about a third of paediatric cancers
in Australia, whereas international percentages ranged from 27%
of paediatric cancers in the United States, (Linabery and Ross,
2008) 30% in Ireland (Stack et al, 2007) and France, (Desandes
et al, 2004) 33% in Germany (Spix et al, 2008) and 35% in
Shanghai, China (Bao et al, 2009) and Chennai, India (Swami-
nathan et al, 2008). For most countries, including Australia, the
next two commonest childhood cancers were CNS (20–27%) and
lymphoma (8–15%). An exception to this was in Chennai, India,
where lymphomas (20%) were more common than CNS (11%)
(Swaminathan et al, 2008).
There have been widespread reports of an increase in childhood
cancer internationally since the 1970s, increasing annually by 0.6%
per year from 1975 to 2002 in the United States (Ward et al, 2006),
by 1.0% in Europe between 1970 and 1999 (Steliarova-Foucher
et al, 2004), by 1.0% in Sweden between 1960 and 1998 (Dreifaldt
et al, 2004) and by 0.8% per year in Western Germany (1987–
2004). The much higher increase in rates in Eastern Germany
(2.1% per year in 1991–2004) was probably influenced by
incomplete data early in the reporting period (Spix et al, 2008).
A subsequent report from the United States (Linabery and Ross,
2008) found evidence of a plateau in incidence trends, with a non-
significant annual increase of 0.4% in rates between 1992 and 2004.
Our findings in Australia are consistent with this latest report, with
an increasing incidence of childhood cancer in Australia during
the 1980s and mid-1990s, followed by a levelling off in the overall
rate, largely because of the patterns among boys and older
children.
Any discussion of the role of environmental or other risk factors
in the observed trends in childhood cancer is hampered by the
current limited understanding of its aetiology. Although genetic
syndromes and higher birth weight are well-established risk
factors, collectively they account for only a small proportion of
cases (Martin et al, 2005; Johnson et al, 2009).
Changes in trends could also be due to changes in diagnostic,
coding or registration practices (Howard et al, 2008; Spector and
Linabery, 2009). For example, in the United States, the use of
improved imaging technology in diagnosis has been suggested to
explain the increase in childhood brain tumours during the 1980s
(Smith et al, 1998). Our study period did not allow us to ascertain
whether a similar effect held in Australia. Second, registration is
often incomplete at the start of a population-based registry. A
7-year ‘run-in period’ has been suggested as ideal for such
registries (Spix et al, 2008) and this is consistent with our data,
with the establishment of the APCR in 1977, 6 years before full
population-based reporting started in 1983.
It has also been suggested that the observed trends could, in
part, be an artefact of reductions in infant mortality, whereby the
proportion of children at greater risk of various diseases, including
cancer, might be increased (Steliarova-Foucher et al, 2005a). In
Australia, the infant mortality rate has reduced from 9.9 infant
deaths/1000 live births in 1985 to 4.7/1000 in 2005. (ABS, 2007;
Australian Institute of Health and Welfare, 2009), with some
suggestion of a levelling off from 1998 onwards (Australian
Institute of Health and Welfare, 2009). However, it is only
speculative whether this has a direct association with the recent
plateau for childhood cancer incidence.
As in most developed countries, average age at first birth has
increased over recent decades, and there is some evidence,
although inconsistent, of a positive association between maternal
age at birth and risk of childhood cancer. A large US case–control
study using pooled population-based data found, after adjusting
for potential confounders, an 8% increase in overall childhood
cancer risk for each 5-year increase in maternal age, with similar
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Figure 1 Trends in directly age-standardised (world population, per million) incidence rates for childhood cancer in Australia between 1983 and 2006.
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A Swedish cohort study found a similar effect of parental age, but
only for children diagnosed below 5 years of age (Yip et al, 2006).
However, there is evidence that the strength of this maternal age
effect has reduced in recent years, with earlier studies more often
finding a positive association (Johnson et al, 2009; Maule et al,
2009). Exposure to an unknown confounder (for example, an
environmental factor) underlying this apparent association may
have changed over time.
The main strength of the APCR is its complete population
coverage, notification being required by law. Notifications are
sourced from a number of agencies, including cancer registries and
hospital facilities, and are matched against the National Death
Index held by the Australian Institute of Health and Welfare. Cases
are then confirmed and validated as part of the standard APCR
validation processes. There is also quantitative evidence of high
data quality, based on the quantification of the DCO and HV
indices. Because some of the cancers are rare, random fluctuations
in rates may spuriously appear as significant trends, or
alternatively it may seem that statistical power is insufficient to
detect real trends. We have attempted to highlight only real trends
by using conservative parameters in the JoinPoint analysis, but
Table 4 Total incidence counts and annual percentage change (APC) in incidence rates of childhood cancer by diagnostic group and sex, Australia, 1983–
2006
a,b
Trend 1 Trend 2 Trend 3
Diagnostic group
Total number
of cases Years APC (95% CI) Years APC (95% CI) Years
APC
(95% CI)
All children
All cancers 13925 1983–1994 +1.7 (+0.9,+2.5) 1994–2006  0.1 ( 0.7,+0.6)
0–4 years 6454 1983–2006 +0.7 (+0.3, +1.1)
5–9 years 3525 1983–2006 +0.5 ( 0.1, +1.1)
10–14 years 3946 1983–1996 +2.7 (+1.1, +4.2) 1997–2006  1.4 ( 3.3, +0.7)
Leukaemias 4591 1983–2006 +0.9 (+0.3,+1.5)
Lymphomas 1374 1983–2006 +0.7 (+0.0,+1.3)
CNS 3158 1983–1998 +1.7 (+0.6,+2.8) 1998–2006  1.8 ( 4.5,+1.0)
Neuroblastomas 869 1983–2006 +0.2 ( 1.1,+1.4)
Retinoblastomas 357 1983–2006 +0.1 ( 1.1,+1.4)
Renal tumours 735 1983–2006 +0.4 ( 0.7,+1.6)
Hepatic tumours 174 1983–2006 +3.3 (+0.8,+5.9)
Malignant bone tumours 602 1983–2006 +0.3 ( 0.8,+1.3)
Soft tissue sarcomas 820 1983–2006  0.2 ( 1.4,+1.1)
Germ cell tumours 511 1983–2006 +2.3 (+0.9,+3.7)
Malignant epithelial tumours
and melanoma
705 1983–1996 +4.3 (+1.6,+7.0) 1996–2006  5.7 ( 9.1, 2.2)
Boys
All cancers 7684 1983–1994 +1.6 (+0.8,+2.4) 1994–2006  0.4 ( 1.0,+0.3)
Leukaemias 2545 1983–2006 +0.6 (+0.1,+1.2)
Lymphomas 960 1983–2006 +0.5 ( 0.3,+1.3)
CNS 1685 1983–2006 +0.7 ( 0.1,+1.5)
Neuroblastomas 483 1983–1994 +3.0 ( 0.8,+7.0) 1994–2006  4.1 ( 7.4, 0.6)
Retinoblastomas 211 1983–2006 +0.1 ( 1.7,+2.0)
Renal tumours 336 1983–2006 +0.1 ( 1.6,+1.8)
Hepatic tumours 106 1983–2006 +3.7 (+0.5,+7.0)
Malignant bone tumours 319 1983–2006 +0.1 ( 1.3,+1.6)
Soft tissue sarcomas 452 1983–2006  0.5 ( 2.0,+1.1)
Germ cell tumours 253 1983–2006 +2.6 (+0.8,+4.5)
Malignant epithelial tumours
and melanoma
318 1983–1996 +4.3 ( 0.7,+9.5) 1996–2006  7.0 ( 13.0, 0.6)
Girls
All cancers 6241 1983–2006 +0.9 (+0.5,+1.4)
Leukaemias 2046 1983–2006 +1.3 (+0.8,+1.9)
Lymphomas 414 1983–2006 +1.2 ( 0.2,+2.5)
CNS 1473 1983–2006 +0.5 ( 0.3,+1.4)
Neuroblastomas 386 1983–2006 +1.3 ( 0.5,+3.1)
Retinoblastomas 146 1983–2006  0.5 ( 2.4,+1.4)
Renal tumours 399 1983–2006 +0.7 ( 0.7,+2.1)
Hepatic tumours 68 1983–2006 +2.5 (+0.0,+5.0)
Malignant bone tumours 283 1983–2006 +0.5 ( 1.0,+2.0)
Soft tissue sarcomas 368 1983–1992 +7.7 (+0.8,+15.1) 1992–1999  8.0 ( 18.0,+3.2) 1999–2006 +5.5 ( 3.0,+14.9)
Germ cell tumours 258 1983–2006 +2.0 (+0.2,+3.9)
Malignant epithelial tumours
and melanoma
387 1983–2006 +0.5 ( 1.3,+2.5)
aTrends based on incidence rates age-adjusted to the WHO World Standard population Howard et al, 2008.
bAPC indicates Annual Percentage Change, with 95% confidence
intervals in brackets.
cTrends based on incidence rates age-adjusted to the WHO World Standard population Howard et al, 2008.
dAPC indicates Annual Percentage Change,
with 95% confidence intervals in brackets. Bold type indicates statistical significance at the 0.05 level.
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caution.
It is encouraging that there is some evidence of a plateau or
reduction in childhood cancer incidence rates in Australia, driven
largely by rates among boys, although we have limited under-
standing of what is driving these changes. The incidence changes
reported here may reflect random variation or changes in
unknown risk factors, and therefore highlight the need for more
research into the aetiology of childhood cancer.
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